Gni Group's Gyre achieves positive F351 trial, announces public offering

Gni Group (TSE:2160) announced that its key subsidiary, Gyre Therapeutics, Inc. ("GYRE"), has achieved the primary endpoint in a pivotal Phase 3 clinical trial in China for F351 (Hydronidone), a treatment for liver fibrosis caused by chronic hepatitis B ("CHB"). The trial demonstrated statistically significant fibrosis regression compared to placebo. GYRE plans to seek rapid approval in China and submit a New Drug Application (NDA) to the NMPA in the third quarter of 2025.